Novo Nordisk has said that it is working with the FDA to make consumers aware of the counterfeits<\/p>\n<\/h3>\n
By Physician\u2019s Briefing Staff HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, Nov. 8, 2023 (HealthDay News) — The U.S. Food and Drug Administration has received at least three reports of people being hospitalized after taking counterfeit versions of semaglutide.<\/p>\n
At least one of these reports includes mention of a counterfeit version of the Novo Nordisk medication Ozempic, CBS News<\/em> reported. Ozempic and Wegovy, another semaglutide medication made by Novo Nordisk, have been tough to find for months as millions of Americans turn to them for weight loss.<\/p>\n In total, 42 reports that mention the use of counterfeit semaglutide were submitted to the FDA Adverse Event Reporting System through the end of September, CBS News<\/em> reported. Of those, 28 were classified as “serious,” with outcomes that included deaths. All were submitted to the FDA by Novo Nordisk.<\/p>\n However, the records do not prove the counterfeits directly caused the adverse events. An FDA spokesperson told CBS News<\/em> that the agency has “no new information to share regarding reports of adverse events” linked to semaglutide counterfeits.<\/p>\n Meanwhile, Novo Nordisk has said that it is working with the FDA to make consumers aware of the counterfeits and how they differ from the company’s products.<\/p>\n “In close collaboration with FDA, we have taken measures to create awareness of the potential for counterfeit products. We have developed a company statement<\/a> that… includes a guide for identifying counterfeits,” a Novo Nordisk spokesperson told CBS News<\/em>.<\/p>\n